Calidi Biotherapeutics (CLDI) Stock Price, News & Analysis

Company Overview

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors. Both programs leverage the company’s proprietary immune activator to induce rapid cytokine release and recruitment of innate and adaptive immune cells at the tumor site. Preclinical studies have also demonstrated potential for a systemically delivered candidate under investigation for metastatic solid tumors. In addition, Calidi maintains a pipeline of preclinical programs exploring prophylactic and therapeutic applications against viral pathogens.

Headquartered in South San Francisco, California, Calidi Biotherapeutics was founded to advance synthetic RNA-based immunomodulators into the clinic and is led by a management team with extensive experience in immuno-oncology drug development. The company collaborates with academic partners and contract manufacturing organizations to support clinical and regulatory activities. Calidi Biotherapeutics is publicly traded on the New York Stock Exchange under the symbol CLDI.

Key Stats

• Today's Range: $1.56 to $1.70
• 50-Day Range: $1.49 to $2.80
• 52-Week Range: $1.48 to $96.95
• Volume: 231,099 shs
• Average Volume: 480,765 shs
• Market Capitalization: $1.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Calidi Biotherapeutics Stock Analysis - MarketRank™

Calidi Biotherapeutics scored higher than 14% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Calidi Biotherapeutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Calidi Biotherapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Calidi Biotherapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Calidi Biotherapeutics has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

20.03% of the float of Calidi Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Calidi Biotherapeutics has a short interest ratio ("days to cover") of 0.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Calidi Biotherapeutics has recently decreased by 93.24%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Calidi Biotherapeutics does not currently pay a dividend.

Dividend Growth

Calidi Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Calidi Biotherapeutics this week, compared to 1 article on an average week.

Search Interest

1 people have searched for CLDI on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Calidi Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.30% of the stock of Calidi Biotherapeutics is held by insiders.

Percentage Held by Institutions

12.53% of the stock of Calidi Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSEAMERICAN:CLDI
• Previous Symbol: NYSE:CLDI
• CIK: 1855485
• Web: calidibio.com
• Phone: 858-794-9600
• Fax: N/A
• Employees: 38
• Year Founded: 2014

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.91 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -424.58%
• Return on Assets: -182.38%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 1.92
• Quick Ratio: 1.92

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.33 per share
• Price / Book: 0.20

Miscellaneous

• Outstanding Shares: 1,210,000
• Free Float: 1,155,000
• Market Cap: $1.98 million
• Optionable: N/A
• Beta: 1.33